Taizhou Mabtech Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Taizhou United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03206151
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Taizhou Mabtech Pharmaceutical Co.,Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Colorectal Neoplasms (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 8